COVID-19 Testing at the Point of Care: NEW PLATFORM FOR HIGH SENSITIVITY ANTIGEN AND ANTIBODY TESTING

Wednesday, September 29, 2:45 – 3:45 p.m.
Exhibit Hall, Theater 2
Supported by LumiraDx

Overview

This symposium will introduce the technology behind the LumiraDx Platform, which is a next generation, point of care diagnostic system, and discuss the clinical performance of the platform in the context of COVID-19 antibody and antigen testing. The session will feature data to showcase the value of using this high sensitivity platform in COVID-19 testing and introduce the latest data from our vaccine study looking at the science behind Ab testing in the vaccinated population. It is a multi-parameter portable test platform and uniquely able to run both COVID-19 antigen and antibody tests, as well as having many other parameters in development. 

Outcomes

After attending this session, participants will be able to:

  • Describe the LumiraDx Platform technology.
  • Discuss the performance of the LumiraDx Antigen test relative to PCR, and its clinical applicability.
  • Discuss the performance of the LumiraDx Antibody test relative to central laboratory technologies.

Speakers

William Clarke, PhD, MBA, DABCC
Professor of Pathology
Johns Hopkins University School of Medicine
Baltimore, MD

Nigel Lindner, PhD
Chief Innovation Officer
LumiraDX
London, United Kingdom